Όλο το DSpace

Πλοήγηση ανά Θέμα "Factor Xa Inhibitors"

Αποτελέσματα 1-8 από 8

    • Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial 

      Kasner S.E., Lavados P., Sharma M., Wang Y., Wang Y., Dávalos A., Shamalov N., Cunha L., Lindgren A., Mikulik R., Arauz A., Lang W., Czlonkowska A., Eckstein J., Gagliardi R., Amarenco P., Ameriso S.F., Tatlisumak T., Veltkamp R., Hankey G.J., Toni D.S., Bereczki D., Uchiyama S., Ntaios G., Yoon B.-W., Brouns R., DeVries Basson M.M., Endres M., Muir K., Bornstein N., Ozturk S., O'Donnell M., Mundl H., Pater C., Weitz J., Peacock W.F., Swaminathan B., Kirsch B., Berkowitz S.D., Peters G., Pare G., Themeles E., Shoamanesh A., Connolly S.J., Hart R.G., NAVIGATE ESUS Steering Committee and Investigators (2018)
      Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing ...

    • Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis 

      Ntaios G., Swaminathan B., Berkowitz S.D., Gagliardi R.J., Lang W., Siegler J.E., Lavados P., Mundl H., Bornstein N., Meseguer E., Amarenco P., Cucchiara B., Camps-Renom P., Makaritsis K., Korompoki E., Papavasileiou V., Marti-Fabregas J., Milionis H., Vemmos K., Connolly S.J., Hart R.G. (2019)
      Background and Purpose - The sources of emboli in patients with embolic stroke of undetermined source (ESUS) are multiple and may not respond uniformly to anticoagulation. In this exploratory subgroup analysis of patients ...

    • Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis 

      Karathanos C., Nana P., Spanos K., Kouvelos G., Brotis A., Matsagas M., Giannoukas A. (2021)
      Objective: Direct oral anticoagulants (DOACs) have been recommended for the treatment of deep vein thrombosis (DVT). However, the benefits are uncertain for the prevention of post-thrombotic syndrome (PTS). We performed a ...

    • Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy 

      Ameriso S.F., Amarenco P., Pearce L.A., Perera K.S., Ntaios G., Lang W., Bereczki D., Uchiyama S., Kasner S.E., Yoon B.-W., Lavados P., Firstenfeld A., Mikulik R., Povedano G.P., Ferrari J., Mundl H., Berkowitz S.D., Connolly S.J., Hart R.G. (2020)
      Background: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of ...

    • Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke 

      Diener H.-C., Ntaios G., O’Donnell M., Easton J.D. (2018)
      Introduction: In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60–70% relative ...

    • Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial 

      Hart R.G., Veltkamp R.C., Sheridan P., Sharma M., Kasner S.E., Bangdiwala S.I., Ntaios G., Shoamanesh A., Ameriso S.F., Toni D., Czlonkowska A., Lindgren A., Hankey G.J., Perera K.S., Shuaib A., Coutts S.B., Gagliardi R.J., Berkowitz S.D., Mundl H., Peters G., Connolly S.J., NAVIGATE ESUS Investigators (2019)
      Background: Embolic stroke of undetermined source (ESUS) identifies patients with cryptogenic ischemic stroke presumed due to embolism from several unidentified sources. Among patients with recent ESUS, we sought to determine ...

    • Recurrent Stroke with Rivaroxaban Compared with Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial 

      Healey J.S., Gladstone D.J., Swaminathan B., Eckstein J., Mundl H., Epstein A.E., Haeusler K.G., Mikulik R., Kasner S.E., Toni D., Arauz A., Ntaios G., Hankey G.J., Perera K., Pagola J., Shuaib A., Lutsep H., Yang X., Uchiyama S., Endres M., Coutts S.B., Karliński M., Czlonkowska A., Molina C.A., Santo G., Berkowitz S.D., Hart R.G., Connolly S.J. (2019)
      Importance: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it ...

    • Rivaroxaban for stroke prevention after embolic stroke of undetermined source 

      Hart R.G., Sharma M., Mundl H., Kasner S.E., Bangdiwala S.I., Berkowitz S.D., Swaminathan B., Lavados P., Wang Y., Wang Y., Davalos A., Shamalov N., Mikulik R., Cunha L., Lindgren A., Arauz A., Lang W., Czlonkowska A., Eckstein J., Gagliardi R.J., Amarenco P., Ameriso S.F., Tatlisumak T., Veltkamp R., Hankey G.J., Toni D., Bereczki D., Uchiyama S., Ntaios G., Yoon B.-W., Brouns R., Endres M., Muir K.W., Bornstein N., Ozturk S., O'Donnell M.J., De Vries Basson M.M., Pare G., Pater C., Kirsch B., Sheridan P., Peters G., Weitz J.I., Peacock W.F., Shoamanesh A., Benavente O.R., Joyner C., Themeles E., Connolly S.J., for the NAVIGATE ESUS Investigators (2018)
      BACKGROUND Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a ...